BGI SENTIS™

Comprehensive Hereditary Cancer

NGS Panel



INTRODUCTION

Individuals with a family history of cancer may have an increased risk of cancer if they have inherited a cancer-causing mutation. Different gene mutations can cause diverse types of cancer. The BGI SENTIS™ Hereditary Cancer Panel analyzes germline mutations across **79 genes** associated with **24 types of hereditary cancer**, including some of the most common cancer types, such as hereditary breast, ovarian, colorectal, prostate, and stomach cancer. Identification of cancer-causing mutations can help guide treatment and health management decisions or guide further testing of at-risk relatives.

ADVANTAGES

Comprehensive

» Whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications and rearrangements*

Flexible

» Choose from versatile testing options with multiple cancer-specific subpanels, including female hereditary cancer, male hereditary cancer, breast/ovarian cancer, colorectal cancer, and more.

Easy-to-use

» Experience a streamlined sample-to-results workflow with our platform and automated on-premises NGS bioinformatics system, enabling effortless obtainment of insightful reports from samples.

* Alterations in methylation and complex genomic aberrations such as uniparental disomy, balanced translocation, inversions, ploidy changes, duplication and deletion of large DNA fragments and/or other rare alternations are not included. Also, there are some regions that cannot be fully covered, including exon15 of CHEK2 gene, and exon1 of STK11 gene.

For Research Use Only. Not for use in diagnostic procedures.

HEREDITARY CANCER SCREENING PRODUCTS

Product Name	Test Content
Sentis Hereditary Cancer Panel (Female)	74 Genes 23 Cancer Types
Sentis Hereditary Cancer Panel (Male)	79 Genes 22 Cancer Types
Sentis Hereditary Breast and Ovarian Cancer	2 Genes/26 Genes
Sentis Hereditary Colorectal Cancer	23 Genes
Sentis Hereditary Prostate Cancer	23 Genes
Sentis Hereditary Pancreatic Cancer	12 Genes

LABORATORY WORKFLOW SOLUTION



DNA Extraction and QC

Targeted Capture and NGS

Data Analysis and Interpretation

NGS Testing Report from Halos Pipeline

BGI's early access program enables your end-to-end testing of various sample types with the following proven products/platforms **(RUO in the US and Canada)**.

MGISP-100* Automated Sample Preparation System

DNBSEQ-G400* Sequencer

BGI Halos Health Analysis in One-Step

SENTIS™ Cancer+ Discovery Panel Reagent Set

**The automation and sequencing instruments are supplied by Complete Genomics directly.*

For Research Use Only. Not for use in diagnostic procedures.

www.bgi.com/us
bgi-discover@bgi.com

Copyright© BGI 2023. All trademarks are the property of BGI or their respective owners. This material contains information on products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.

@BGI Genomics